Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.
It is estimated that about a third of the population live with some form of muscle or joint problem and those most severely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback